Correction: Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial

• Farastuk Bozorgmehr,
• Inn Chung,
• Petros Christopoulos,
• Johannes Krisam,
• Marc A. Schneider,
• Lena Brückner,
• Daniel Wilhelm Mueller,
• Michael Thomas,
• Stefan Rieken

Affiliations

Farastuk Bozorgmehr

Department of thoracic oncology, Thoraxklinik at University Hospital of Heidelberg

Inn Chung

Department of thoracic oncology, Thoraxklinik at University Hospital of Heidelberg

Petros Christopoulos

Department of thoracic oncology, Thoraxklinik at University Hospital of Heidelberg

Johannes Krisam

Institute of Medical Biometry and Informatics, University Hospital of Heidelberg

Marc A. Schneider

Translational Lung Research Center Heidelberg TLRCH, Member of the german Center for Lung Research DZL

Lena Brückner

Department of thoracic oncology, Thoraxklinik at University Hospital of Heidelberg

Daniel Wilhelm Mueller

Institute of Clinical Cancer Research IKF GmbH at Northwest Hospital

Michael Thomas

Department of thoracic oncology, Thoraxklinik at University Hospital of Heidelberg

Stefan Rieken

Department of Radiation Oncology, University Medical Center Göttingen